Patents by Inventor Zhijian Zhuo

Zhijian Zhuo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
    Patent number: 11859215
    Abstract: This disclosure relates mRNA therapy for the treatment of ornithine transcarbamylase deficiency (OTCD). mRNAs for use in the invention, when administered in vivo, encode human ornithine transcarbamylase (OTC), isoforms thereof, functional fragments thereof, and fusion proteins comprising OTC. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of OTC expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic ammonia associated with deficient OTC activity in subjects.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: January 2, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Zhijian Zhuo, Andrea Lea Frassetto, Paolo G. V. Martini, Vladimir Presnyak, Patrick Finn
  • POLYNUCLEOTIDES ENCODING ORNITHINE TRANSCARBAMYLASE FOR THE TREATMENT OF UREA CYCLE DISORDERS
    Publication number: 20200299652
    Abstract: This disclosure relates mRNA therapy for the treatment of ornithine transcarbamylase deficiency (OTCD). mRNAs for use in the invention, when administered in vivo, encode human ornithine transcarbamylase (OTC), isoforms thereof, functional fragments thereof, and fusion proteins comprising OTC. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of OTC expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic ammonia associated with deficient OTC activity in subjects.
    Type: Application
    Filed: November 21, 2018
    Publication date: September 24, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Zhijian Zhuo, Andrea Lea Frassetto, Paolo G.V. Martini, Vladimir Presnyak, Patrick Finn